Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Core Insights - Palatin Technologies, Inc. announced positive results from its BMT-801 Phase 2 obesity study, demonstrating effective appetite suppression with its drug bremelanotide in combination with tirzepatide [1][5] Study Results - The study included three arms: co-administered bremelanotide and tirzepatide, bremelanotide alone, and tirzepatide alone, all showing significant improvements in appetite suppression, fullness, and satiety [3][7] - Patients receiving co-administered bremelanotide and tirzepatide experienced a 71% increase in overall appetite suppression, while tirzepatide alone showed a 73% increase, and bremelanotide alone also showed a 71% increase [8] - Fullness increased by 65% in the co-administered group, 62% in the tirzepatide group, and 79% in the bremelanotide group [8] - Satiety increased by 56% in both the co-administered and tirzepatide groups, while the bremelanotide group showed a 68% increase [8] Weight Maintenance - Over 50% of lost weight was regained within two weeks after stopping tirzepatide, while patients transitioning to low-dose bremelanotide maintained their weight without significant regain, indicating its potential for long-term weight management [4][6] Pipeline Development - Palatin is advancing next-generation MC4R agonists, including long-acting peptides and oral small molecules, targeting various obesity indications and rare genetic obesity disorders, with IND filings expected by the end of Q4 2025 and initial clinical data anticipated in the first half of 2026 [6][11] Company Overview - Palatin Technologies focuses on developing first-in-class medicines that modulate the melanocortin receptor system, aiming to address significant unmet medical needs and maximize commercial potential through strategic collaborations [11]